Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health Cuts Q2 Loss in Half as Product Revenue Surges; Shares Jump 15 Percent

NEW YORK (GenomeWeb News) – Genomic Health said today net loss fell by nearly half in the second quarter as product revenues quintupled.
The results caused shares in the company to trade up almost 15 percent, or $1.61, at $12.47 in mid-afternoon today.
Receipts for the three months ended June 30 increased to $8.4 million from $1.2 million year over year, Genomic Health said. Oncotype DX product sales to Medicare and privately insured patients accounted for $7.8 million in revenue.
R&D costs increased 13 percent to $2.8 million from $2.4 million in the comparable quarter a year ago.
Genomic Health narrowed its net loss 39 percent in the quarter to $4.9 million from $8 million during the comparable period last year.
The company said it had around $21 million in cash and cash equivalents and $33.7 million in short-term investments as of June 30.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.